StreetInsider.com News Articles

Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Fri, 29 May 2026 09:00:00 -0400

ORLANDO, FL / ACCESS Newswire / May 29, 2026 / RedChip Companies will air interviews with Foremost Clean Energy Ltd. (Nasdaq:FMST)(CSE:FAT) and BioVie, Inc. (Nasdaq:BIVI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 30, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Access the interviews in their entirety at:

Jason Barnard, President and CEO of Foremost Clean Energy, appears on the RedChip Small Stocks Big Money™ show on

Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Fri, 29 May 2026 09:00:00 -0400

Access the interviews in their entirety at:

Jason Barnard, President and CEO of Foremost Clean Energy, appears on the RedChip Small Stocks Big Money™ show on

Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Fri, 29 May 2026 09:00:00 -0400

Access the interviews in their entirety at:

Jason Barnard, President and CEO of Foremost Clean Energy, appears on the RedChip Small Stocks Big Money™ show on

Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Fri, 29 May 2026 09:00:00 -0400

Access the interviews in their entirety at:

Jason Barnard, President and CEO of Foremost Clean Energy, appears on the RedChip Small Stocks Big Money™ show on

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

Wed, 27 May 2026 08:00:00 -0400

CARSON CITY, Nev., May 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on June 2, 2026, at 4:15 p.m. ET.

The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), the Company’s investigational oral drug candidate that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

Wed, 27 May 2026 08:00:00 -0400

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

Wed, 27 May 2026 08:00:00 -0400

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

Wed, 27 May 2026 08:00:00 -0400

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

Wed, 27 May 2026 08:00:00 -0400

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

Wed, 27 May 2026 08:00:00 -0400

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

Wed, 27 May 2026 08:00:00 -0400

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

Wed, 27 May 2026 08:00:00 -0400

BioVie completes enrollment in long COVID treatment trial

Tue, 26 May 2026 08:01:40 -0400

BioVie Inc. (NASDAQ: BIVI) announced it has fully enrolled its ADDRESS-LC Phase 2 trial evaluating bezisterim for treating neurological symptoms associated with long COVID. The company expects to release topline data in late summer 2026.

The randomized, placebo-controlled trial is comparing bezisterim, administered as a 20 mg oral capsule twice daily, against placebo in adult participants with long COVID who experience cognitive impairment and fatigue. The study is fully funded by a $13.13 million grant from the U.S. Department of War through the Peer-Reviewed Medical Research Program.

The primary endpoint measures changes in performance on a Cogstate Cognitive Battery designed to assess

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

Tue, 26 May 2026 08:00:00 -0400

-Topline Data Release Targeted Late Summer 2026-

CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced full enrollment of the Company’s ADDRESS-LC Phase 2 trial evaluating its drug candidate bezisterim for the treatment of neurological symptoms of Long COVID. The Phase 2 study is fully funded by a grant from the U.S. Department of War (DoW, formerly the U.S. Department of Defense).